Demonstration of alpha-synuclein immunoreactivity in neuronal and glial cytoplasm in normal human brain tissue using proteinase K and formic acid pretreatment.
about
Molecular Pathological Classification of Neurodegenerative Diseases: Turning towards Precision MedicineNeuronal response in Alzheimer's and Parkinson's disease: the effect of toxic proteins on intracellular pathwaysThe complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's diseaseThe involvement of microRNAs in neurodegenerative diseasesAlpha-synuclein biology in Lewy body diseasesAnimal modeling an oligodendrogliopathy--multiple system atrophyAcyl-CoA synthetase activity links wild-type but not mutant alpha-synuclein to brain arachidonate metabolismEvaluation of alpha-synuclein immunohistochemical methods used by invited expertsAstrocytic expression of Parkinson's disease-related A53T alpha-synuclein causes neurodegeneration in mice.Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.Glial innate immunity generated by non-aggregated alpha-synuclein in mouse: differences between wild-type and Parkinson's disease-linked mutants.17-AAG induces cytoplasmic alpha-synuclein aggregate clearance by induction of autophagyDirect transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies.Altered lipid levels provide evidence for myelin dysfunction in multiple system atrophy.Interleukin-1 mediates Alzheimer and Lewy body pathologies.Glial cell inclusions and the pathogenesis of neurodegenerative diseasesAltered serum IgG levels to α-synuclein in dementia with Lewy bodies and Alzheimer's disease.α-Synuclein levels are elevated in cerebrospinal fluid following traumatic brain injury in infants and children: the effect of therapeutic hypothermia.Misfolded, protease-resistant proteins in animal models and human neurodegenerative diseaseExpression of mutant alpha-synuclein modulates microglial phenotype in vitroAntigen retrieval to improve the immunocytochemistry detection of sigma-1 receptors and ER chaperones.Aggregation of αSynuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neuronsBrain prostaglandin formation is increased by alpha-synuclein gene-ablation during global ischemia.Cellular pathology in multiple system atrophy.Immunological features of alpha-synuclein in Parkinson's disease.Lipopolysaccharide-induced blood brain barrier permeability is enhanced by alpha-synuclein expressionTau-positive glial cytoplasmic granules in multiple system atrophy.Unraveling the role of peptidyl-prolyl isomerases in neurodegeneration.Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts.α-Synuclein in Parkinson's disease.Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease?The role of glia in α-synucleinopathies.Dysfunction of two lysosome degradation pathways of α-synuclein in Parkinson's disease: potential therapeutic targets?The role of inflammation in sporadic and familial Parkinson's disease.Inclusion body formation, macroautophagy, and the role of HDAC6 in neurodegeneration.Neuropathology of α-synuclein propagation and braak hypothesis.The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases.Oxidative stress promotes uptake, accumulation, and oligomerization of extracellular α-synuclein in oligodendrocytes.miRNAs as biomarkers of neurodegenerative disorders.α-Synuclein deficiency promotes neuroinflammation by increasing Th1 cell-mediated immune responses.
P2860
Q26768648-30F3DCB0-ADE9-426A-B426-2035E81BBBC3Q26779424-AA493DA1-AE37-4F0D-9283-F494EF0CD03AQ26853537-82138193-5849-4CCF-8DC3-1494510937FEQ26858788-FCCDA1A6-B04D-44B2-95E6-88F786C2D13CQ27003541-EAFF8A02-CD0A-47B5-9ABE-060F608061F4Q28074659-0A7766CF-0BF0-47A9-A4C9-9A4B2E243D72Q28586519-3DD63CC3-6745-4F6A-BB9C-07C2CADFE94EQ30488694-90EDC5B8-2CFF-4F41-9760-20967EE9DC8DQ30494594-57CC90D3-D3DD-4D9C-A475-A293EC2795EBQ30856480-DC43DFF8-0159-4132-9711-30E7206DE6EFQ30991616-5B35AE93-0ECB-4E22-A4A8-E1BC8E9E9F84Q33525555-94F9B090-DC26-4275-AA05-FF05E7E93083Q33726660-5EA71E32-F09C-49A5-8267-7CCB81CB9EE4Q34491408-D7DC0D9F-D20F-461A-83F3-FA0D0D127762Q34537594-63974193-007F-4B1E-8952-7A7C6DEFA6AEQ34538330-26A1DD02-0192-4605-BC5B-CC8CDE1728F3Q34760606-D740C85D-7685-4B76-B31E-58DB3AB4A42EQ34777956-05DA037A-09F6-445E-BDAD-28C3C5CD42E7Q35001612-1EBC184A-1AF7-4071-8BA2-94AEB02B16D4Q35014520-4C62FE08-8F84-4AB4-8411-657150529CB0Q35163203-1BB55447-14CE-415D-8986-DA1733A67533Q35863939-6B377EC7-D9B2-43F9-B891-8D1347CE61E9Q36507462-F4ABFB81-0962-4689-88C7-4BB579579EE4Q36589164-1A6EC057-0599-4665-9399-01313E9E9AC2Q37232067-D8AF9299-8EFD-4910-9B8B-779D1CB0B382Q37237861-8ECFF5EA-A2A5-49A4-85DB-795A71A9CE7CQ37808274-C0B62DCC-F041-4F39-9C51-04BFBD128388Q37873359-7A3D2E9F-19E1-43F8-9DAE-8DAA4C60CF29Q37874476-A6FA1AEC-2A9E-45A1-93D4-68CCF41FC11CQ37987146-DF58C32E-1D22-4197-B891-522842FDACFBQ38014888-B43A1367-370D-439A-A93D-B5139A8CB6E5Q38039880-E560DEF3-2D54-4CBF-AC75-DDA34292ACBBQ38041991-011C9ACC-FA35-4726-BD2B-180E8275E7C3Q38105903-A67675BC-2AE7-4EBF-9051-429184AFC9E1Q38126332-762490FC-A112-41FF-BCB3-CC90B07679A6Q38580816-C231A1BD-3C38-47BF-BFDA-E68AE8A4731AQ39052041-C70F1A28-06C7-4886-91B2-04736457A976Q39064365-39F2A30D-0182-4BDE-A421-467008D75C2FQ39104808-68B599E2-2119-421C-A613-6710AC012E91Q40960833-299FF2BA-D7A8-4F94-B39F-B3EE4DF8D949
P2860
Demonstration of alpha-synuclein immunoreactivity in neuronal and glial cytoplasm in normal human brain tissue using proteinase K and formic acid pretreatment.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Demonstration of alpha-synucle ...... and formic acid pretreatment.
@ast
Demonstration of alpha-synucle ...... and formic acid pretreatment.
@en
Demonstration of alpha-synucle ...... and formic acid pretreatment.
@nl
type
label
Demonstration of alpha-synucle ...... and formic acid pretreatment.
@ast
Demonstration of alpha-synucle ...... and formic acid pretreatment.
@en
Demonstration of alpha-synucle ...... and formic acid pretreatment.
@nl
prefLabel
Demonstration of alpha-synucle ...... and formic acid pretreatment.
@ast
Demonstration of alpha-synucle ...... and formic acid pretreatment.
@en
Demonstration of alpha-synucle ...... and formic acid pretreatment.
@nl
P2093
P356
P1476
Demonstration of alpha-synucle ...... and formic acid pretreatment.
@en
P2093
Fumiaki Mori
Hitoshi Takahashi
Koichi Wakabayashi
Kunikazu Tanji
Makoto Yoshimoto
P304
P356
10.1006/EXNR.2002.7929
P407
P577
2002-07-01T00:00:00Z